Galectin Therapeutics Inc. (NASDAQ:GALT) – Equities researchers at FBR & Co decreased their FY2017 earnings per share estimates for Galectin Therapeutics in a report released on Monday. FBR & Co analyst V. Bernardino now anticipates that the firm will earn ($1.09) per share for the year, down from their prior forecast of $0.50. FBR & Co has a “Market Perform” rating and a $2.00 price objective on the stock. FBR & Co also issued estimates for Galectin Therapeutics’ FY2018 earnings at ($0.71) EPS, FY2019 earnings at ($0.88) EPS and FY2020 earnings at ($0.50) EPS.
Galectin Therapeutics (NASDAQ:GALT) last posted its quarterly earnings results on Tuesday, August 9th. The company reported ($0.20) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.24) by $0.04.
GALT has been the topic of several other reports. Roth Capital assumed coverage on Galectin Therapeutics in a research report on Friday, July 1st. They issued a “buy” rating on the stock. Zacks Investment Research raised Galectin Therapeutics from a “hold” rating to a “buy” rating and set a $2.25 price objective on the stock in a research report on Monday, August 15th. Finally, HC Wainwright cut Galectin Therapeutics from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $8.00 to $1.50 in a research report on Thursday, September 29th.
Galectin Therapeutics (NASDAQ:GALT) traded down 2.9604% during midday trading on Wednesday, reaching $0.9801. The company had a trading volume of 214,813 shares. The company’s market capitalization is $28.70 million. The firm has a 50-day moving average price of $1.77 and a 200-day moving average price of $1.60. Galectin Therapeutics has a 52 week low of $0.94 and a 52 week high of $3.25.
A number of large investors have recently made changes to their positions in the stock. BlackRock Fund Advisors raised its stake in shares of Galectin Therapeutics by 33.8% in the second quarter. BlackRock Fund Advisors now owns 78,955 shares of the company’s stock worth $116,000 after buying an additional 19,967 shares in the last quarter. Advisor Group Inc. bought a new stake in shares of Galectin Therapeutics during the second quarter worth $584,000. Finally, Vanguard Group Inc. raised its stake in shares of Galectin Therapeutics by 0.4% in the second quarter. Vanguard Group Inc. now owns 606,537 shares of the company’s stock worth $892,000 after buying an additional 2,490 shares in the last quarter. Institutional investors and hedge funds own 11.69% of the company’s stock.
Galectin Therapeutics Company Profile
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.
Receive News & Ratings for Galectin Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.